Kornitzer Capital Management Inc. KS Buys 62,000 Shares of Bruker Co. (NASDAQ:BRKR)

Kornitzer Capital Management Inc. KS boosted its holdings in shares of Bruker Co. (NASDAQ:BRKR - Free Report) by 74.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 145,000 shares of the medical research company's stock after purchasing an additional 62,000 shares during the period. Kornitzer Capital Management Inc. KS owned 0.10% of Bruker worth $8,500,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. True Wealth Design LLC increased its stake in shares of Bruker by 4,636.4% in the third quarter. True Wealth Design LLC now owns 521 shares of the medical research company's stock valued at $36,000 after buying an additional 510 shares in the last quarter. Eagle Bay Advisors LLC grew its stake in shares of Bruker by 2,324.1% during the fourth quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company's stock valued at $41,000 after purchasing an additional 674 shares during the last quarter. UMB Bank n.a. increased its holdings in shares of Bruker by 37.5% in the fourth quarter. UMB Bank n.a. now owns 909 shares of the medical research company's stock valued at $53,000 after purchasing an additional 248 shares in the last quarter. Values First Advisors Inc. bought a new position in Bruker in the 3rd quarter worth approximately $73,000. Finally, GAMMA Investing LLC lifted its holdings in Bruker by 47.5% during the 4th quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company's stock worth $75,000 after buying an additional 412 shares in the last quarter. Institutional investors own 79.52% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on BRKR shares. Guggenheim restated a "buy" rating on shares of Bruker in a research report on Friday, January 17th. Stifel Nicolaus cut their target price on shares of Bruker from $70.00 to $57.00 and set a "hold" rating on the stock in a research report on Friday, February 14th. Barclays cut their price objective on shares of Bruker from $69.00 to $65.00 and set an "overweight" rating on the stock in a report on Monday, February 10th. Bank of America lifted their target price on shares of Bruker from $78.00 to $80.00 and gave the stock a "buy" rating in a report on Friday, December 13th. Finally, The Goldman Sachs Group raised Bruker from a "sell" rating to a "neutral" rating and set a $60.00 price target on the stock in a research note on Thursday, December 5th. Six research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, Bruker presently has an average rating of "Moderate Buy" and a consensus price target of $70.50.

Bruker Trading Down 4.0 %

NASDAQ:BRKR traded down $2.10 on Friday, reaching $50.82. The company's stock had a trading volume of 2,050,917 shares, compared to its average volume of 1,640,696. The firm has a market cap of $7.70 billion, a PE ratio of 66.87, a PEG ratio of 2.16 and a beta of 1.16. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60. The business's 50-day moving average price is $56.73 and its two-hundred day moving average price is $60.05. Bruker Co. has a 1-year low of $48.07 and a 1-year high of $94.86.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its earnings results on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, topping the consensus estimate of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. Equities research analysts anticipate that Bruker Co. will post 2.69 earnings per share for the current fiscal year.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.